Clinical Trial: ALSENLITE: Senolytics for Alzheimer's Disease

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT04785300) titled 'ALSENLITE: Senolytics for Alzheimer's Disease' on March 4.

Brief Summary: This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

Study Type: Interventional

Condition: * Mild Cognitive Impairment

* Alzheimer Disease

Intervention: * Drug: Dasatinib

100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles

* Drug: Quercetin

Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days ...